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A B S T R A C T   
Background: Interest has risen in identifying individuals at high risk of incident Parkinson’s disease (PD) to facilitate inclusion in neuroprotective treatment trials. 
Current risk estimates of prodromal markers are based on aggregated data of an entire population, but this approach disregards differences in risk estimates by 
subgroups of a population. In this proof of concept, we determine subgroup-specific risk estimates of olfactory dysfunction for incident PD. 
Methods: PubMed, EMBASE and Cochrane were searched for prospective studies investigating the association between olfactory dysfunction and incident PD. 
Random-effects meta-analysis, subgroup analyses and meta-regression were performed to investigate general and subgroup risk estimates. 
Results: Individuals with odor identification dysfunction seemed to be at greater risk of incident PD compared to controls without olfactory dysfunction (OR = 4.18; 
95%CI [2.47–7.07]). Risk estimates were higher in studies that included higher percentages of women (regression slope β = 0.053 increase in log odds ratio per 1% 
increase 1%, p = 0.0006), increased with mean study age (β = 0.21 per one year increase; p = 0.005) and in REM-sleep behavior disorder cohorts (β = 1.95; p =
0.03). Furthermore, the association between olfactory dysfunction and incident PD was most distinct in studies with shorter follow-up duration (ß = − 0.56; p =
0.0047). 
Conclusion: The presence of olfactory dysfunction conveys a considerably elevated risk of incident PD, likely more in studies with a higher proportion of women, older 
individuals or short follow-up duration. Individual patient data are warranted to confirm these findings and to yield subgroup-specific risk estimates of other common 
markers to refine prodromal PD criteria.   
1. Background 
Parkinson’s disease (PD) is a progressive neurological disorder that is 
often preceded by a prodromal phase that largely consists of non-motor 
features. Olfactory deficits are a common feature of both the prodromal 
and clinically manifest phase of PD [1,2], occurring in approximately 
75% of all PD patients [3]. Various hypotheses have been proposed to 
explain the occurrence of early loss of smell in PD patients, for example 
that the olfactory bulb is affected early on as α-synucleinopathy ascends 
within the nervous system [4]. 
As olfactory dysfunction is present early in the disease course and 
appears to be common, it is regarded as a promising biomarker to timely 
diagnose PD, which may be incorporated in recruitment algorithms for 
neuroprotective treatment trials [5,6]. Recently, interest has risen in 
developing quantitative methods to estimate risk of incident PD based 
on presence of prodromal features, including olfactory dysfunction, 
REM sleep behavior disorder (RBD) and other factors [7]. Note that the 
current Movement Disorder Society (MDS) criteria for (prodromal) PD 
only provide overall estimates of the risk of incident PD based on these 
features [8,9]. However, this approach may disregard differences in risk 
by subgroup, as the specificity of a putative prodromal feature for PD 
pathology could vary depending on the characteristics of a patient 
subgroup. For example, a clinician would be much more aware of the 
risk of clinical PD if olfactory dysfunction occurred in an individual with 
RBD than in an individual without RBD. To date, however, empirical 
data assessing risk estimates of olfactory dysfunction by subgroup are 
scarce. 
To address this key gap in knowledge, we aimed to unravel the 
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association between olfactory dysfunction and incident PD by meta- 
analyzing all published longitudinal studies, with a particular focus on 
subgroup-specific estimates based on age, sex, presence of RBD, and 
latency until diagnosis of PD after detection of olfactory dysfunction. 
2. Methods 
2.1. Search strategy 
PRISMA guidelines for conducting and reporting systematic research 
were used. PubMed, EMBASE and Cochrane databases were searched for 
eligible studies up-to-date until July 4, 2020. The search strategy is 
detailed in the Supplementary material. Reference lists of the included 
articles were hand-searched for additional eligible studies. 
2.2. Selection criteria 
Two reviewers (JJD, AT) independently evaluated the eligibility of 
studies. We only included prospective, longitudinal studies while we 
excluded cross-sectional studies in this meta-analysis, because of two 
reasons: prospective studies are less susceptible to selection bias, pro-
vided that there is no selective attrition during follow-up, as well as to 
differential misclassification of olfactory function during the (matched) 
prediagnostic phase of at-risk individuals (i.e., information bias). Dis-
agreements were resolved during a consensus meeting with a third in-
dependent reviewer (SKLD). Studies were included if they fulfilled all 
predefined selection criteria (Supplementary Table 1). No restrictions 
were applied to study population selection criteria to ensure that both 
population-based as well as high-risk trait cohorts (e.g., selection based 
on presence of RBD) were included. All measures of olfactory dysfunc-
tion (such as identification and threshold) were considered. If there was 
more than one article in which a specific cohort was reported and 
analyzed (e.g., if updated estimates from the same cohort were pub-
lished), the article with the most incident cases and if identical the study 
with the longest follow-up was included. If a study pooled multiple 
comparable cohorts, it was assessed if all individual cohorts met the 
inclusion criteria for separate inclusion. If not, the total pooled results 
from the original study were adopted in the current analysis if these met 
the inclusion criteria. With these measures, potential inflation of risk 
estimates due to insufficient cases per study is reduced. This applied to 
one study included in the present meta-analysis. [10] 
2.3. Data extraction and quality assessment 
In a standardized extraction form, the following variables from the 
included articles were collected: first author name, year of publication, 
manuscript title, cohort name, country of cohort, study design, study 
selection criteria (e.g., RBD), number of persons at risk, mean or median 
age at baseline, the proportion of women among those at risk, definition 
of olfactory dysfunction, olfactory testing instrument, mean or median 
duration of follow-up (after detection of olfactory dysfunction, i.e. set 
study length or until diagnosis), diagnostic criteria used for PD, number 
of individuals stratified by olfactory dysfunction and incident PD status 
(clinical diagnosis), age- and sex-adjusted odds ratio (OR) or hazard 
ratio (HR) and 95% confidence interval, number of cases of PD, and 
covariates used in regression model(s). If risk estimates were unavai-
lable, the corresponding author of included articles was contacted to 
provide them to us. A study was interpreted as ‘high-risk’ if it included 
patients with any signs or symptoms other than olfactory dysfunction 
that are suggestive of PD, such as RBD or mild parkinsonian signs. 
Quality assessment was performed for each study using a six-point 
modified Newcastle–Ottawa scale for cohort studies. Compared with 
the original scale, the following two items were removed because they 
were used as selection criteria for an article to be included in the meta- 
analysis [1]: controls had to be drawn from the same cohort as exposed; 
and [2] exposure was measured as part of the study protocol. Similarly, 
as we intended to include both studies with and without age and sex 
adjustment to analyze its modifying effect, we did not intend lack of 
adjustment to be part of the exclusion criteria. Given these modifica-
tions, a sum score was not calculated. A funnel plot and Egger’s test were 
conducted to test for potential publication bias. Egger’s test is a 
regression analysis of the study effect sizes on study precision, essen-
tially returning a numerical value of the asymmetry in the funnel plot 
[11]. 
2.4. Statistical analyses 
Unadjusted and age- and sex-adjusted ORs of olfactory dysfunction 
for incident PD were compiled from each included study. If no unad-
justed OR was provided, an unadjusted OR was calculated based on the 
number of individuals stratified by olfactory dysfunction and incident 
PD status. Only in the meta-analysis regarding age- and sex-adjusted 
odds ratios, the study by Chen et al., which reported a hazard ratio, 
was combined with odds ratios from other studies [12]. Heterogeneity 
across studies was assessed using the I2 statistic. Random effects generic 
inverse variance models were used to meta-analyze unadjusted and, 
separately, age- and sex-adjusted ORs of olfactory dysfunction for inci-
dent PD. If statistical separation occurred (e.g., no normosmic in-
dividuals with subsequent incident PD), one individual was added to 
every stratum to avoid inflation of the OR. Across all analyses, p < 0.05 
was considered to be statistically significant. 
To explore whether the association of olfactory dysfunction with 
incident PD varied by study-level covariates, unadjusted ORs were 
analyzed with a univariate random-effects analysis by analyzing the 
standard error of the difference in the pooled unadjusted meta-analysis 
[13]. Study-level covariates were subdivided based on mean study age 
(≥66.8 or <66.8 years, [this cut-off reflects the median age across the 
included studies]), study percentage of females (≥47.1% or <47.1%, 
median percentage of females across included studies), mean study 
follow-up duration (≥6.2 or <6.2 years after olfactory testing, median 
follow-up across included studies). 
To determine multivariate study-level covariates, a random-effects 
meta-regression analysis was conducted using the unadjusted odds ra-
tios and the following covariates: age, sex and follow-up duration at the 
study level and the olfactory testing instrument. As a sensitivity analysis, 
a Knapp-Hartung modification was added to additionally account for 
heterogeneity [14]. In a separate sensitivity analysis, we added the 
study-level incidence rate of PD as a covariate to the meta-regression, to 
assess whether observed ORs were affected by the number of incident PD 
cases per year in a study. Analyses were performed using R packages 
meta, dmetar and ggplot2 [15–18]. 
3. Results 
3.1. Literature search 
From PubMed, the Cochrane Library and EMBASE, 2304 dedupli-
cated articles were retrieved. After title and abstract screening, the full 
text of 57 articles was evaluated, after which 8 reports were included in 
the final meta-analysis (Supplementary Figure 1). Screening of refer-
enced articles did not result in additional inclusions. 
3.2. Characteristics and quality of included studies 
Eight articles comprising twelve cohorts presented complete cohort 
analyses, while the study of Jennings et al. presented a nested case- 
control analysis. One report concerned five pooled cohorts (Depres-
sion_PD, EPI-PARK, PRIPS-Tübingen, PRIPS-Homburg and TREND) that 
were pooled accordingly in this study as not all individual studies met 
the criteria for separate inclusion [7]. In total, 8441 at-risk individuals 
were included in this meta-analysis. The average number of patients per 
study was 1055, and there were three studies with over 1000 
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individuals. Five studies were conducted in North-America, one in 
Germany, one in Italy and one in Austria. Study-level mean and median 
age at baseline were 68.6 and 66.8 years, respectively (range 
60.0–79.7). Three studies included less than a third of women and three 
studies had female participation of 50% or more (range 0–53.8%, me-
dian percentage 47.1%). Five studies had a sample that was largely 
representative of the general population. Three studies reported 
high-risk cohorts: the study by Montgomery et al. only included in-
dividuals with mild parkinsonian signs, and the studies by Fer-
eshtehnejad et al. and Mahlknecht et al. (2016) only included 
individuals with RBD. Follow-up ranged from 3 to 10 years, and six 
studies reported a follow-up duration longer than 5 years (range 5.7–10 
years, median 6.2 years). Three studies also reported risk estimates for 
the follow-up period after the first 4 or 5 years of follow-up (e.g. in the 
article by Chen et al., for the first 5 years as well as the 5–9.8 year in-
terval. The following olfactory testing instruments were used: B-SIT 
(Brief Smell Identification Test, n = 2), UPSIT (University of Pennsyl-
vania Smell Identification Test, n = 3) and SS-12 or SS-16 (Sniffin’ Sticks 
Identification test, n = 3). The definition of olfactory dysfunction varied 
by study, although all studies used a customary measure of odor iden-
tification (Table 1). Each study provided an OR of the association of 
olfactory dysfunction with incident PD or crude numbers which facili-
tated the calculation of that OR. In addition, half of the studies provided 
a risk estimate (odds ratio [OR] or hazard ratio [HR]) for the association 
between olfactory dysfunction and PD, which was adjusted for age and 
sex. In Table 2 of the Supplementary File, an overview of the modified 
Newcastle-Ottawa scale is included, applied to the included studies. 
Representativeness of studies differed, as some studies included patients 
with RBD or mild parkinsonian signs. (Table 1). Notably, all studies 
reported complete follow-up or complete registration of all at-risk in-
dividuals lost to follow up. The funnel plot of risk estimates showed two 
estimates from high-risk cohorts on the far-right side and no estimates 
on the bottom left. (Supplementary Figure 2; Egger’s test p = 0.22). 
3.3. Association of olfactory dysfunction and incident PD 
Significant heterogeneity in the meta-analysis of unadjusted ORs (I2 
statistic 70.7%, p < 0.01) was found. The unadjusted pooled OR of ol-
factory dysfunction for incident PD was 4.18 [CI 95% 2.47-7.07]. 
Pooling the three high-risk cohorts resulted in an unadjusted OR of 
9.39 [CI 95% 2.42-36.49] compared to the population-based studies 
with an OR of 2.75 [CI 95% 2.11-3.58] with p=0.08. The calculated age- 
and sex-adjusted pooled OR, based on the four studies with available 
data, was 3.12 [CI 95% 2.26-3.98]; by comparison, the pooled unad-
justed OR in these four studies was 2.73 [CI 95% 2.09-3.57]. (see Fig. 1). 
Subgroup analyses of the association between olfactory dysfunction 
and PD are outlined in Table 2. The pooled unadjusted OR was higher in 
RBD (sub)cohorts (OR=5.75) than in other studies and even higher in all 
high-risk cohorts, which includes patients with mild parkinsonian signs 
(OR=9.39). The pooled unadjusted OR for a shorter-than-median 
follow-up duration (<6,2 years after diagnosis of olfactory dysfunc-
tion) was higher than that of studies with a longer follow-up (OR = 7.96 
versus 2.73). OR was higher in studies with higher-than-median mean 
age of 66.8 years compared to studies with a lower-than-median mean 
age (OR = 4.70 versus 2.91). Pooled effects were larger for studies with a 
higher-than-median (≥47.1%) percentage of women (OR = 6.01 versus 
2.69). These subgroup (univariate) differences were not statistically 
significant, although a trend for the association of olfactory dysfunction 
and follow-up duration was observed (p = 0.07), as well as for RBD 
studies versus community-dwelling cohorts.- 
A multivariate random effects meta-regression demonstrated multi-
ple statistically significant study-level covariates, namely study-level 
female percentage (regression slope parameter [β] = +0.053 [increase 
in logOR per unit increase in a study’s female percentage]; p = 0.0006), 
shorter mean study follow-up duration (β = − 0.56 for each increasing 
year of study follow-up; p = 0.0016), increasing mean study age (β =
0.2112 for every unit increase in mean study age; p = 0.0047) and RBD 
(β = 1.95 for exclusively RBD studies; p = 0.034). In Fig. 2, regression 
plots for sex and follow-up are shown. The type of olfaction testing in-
strument used did not significantly influence the risk estimates for 
incident PD in these studies, although a trend of lower OR for Sniffin’ 
Sticks studies was observed (β of [UPSIT or BSIT] vs. [Sniffin Sticks] =
+1.17; p = 0.058). A sensitivity analysis using additional Knapp- 
Hartung modification resulted in an increase of p-values for mean 
study age (p = 0.096), mean study follow-up duration (p = 0.080) and 
mean study sex (p = 0.068). In a separate sensitivity analysis, study 
incidence of PD did not show a significant modifying effect on the 
observed OR (p = 0.46). An additional sensitivity analysis that adjusted 
for high-risk cohorts showed that this was an independent predictor of 
the association between olfactory dysfunction and incident PD (β =
1.49, p = 0.026). Although the covariates study age (p = 0.01) and 
gender (0.0023) were still significant, this was not true for study follow- 
up duration (p = 0.068). 
4. Discussion 
In this study, we observed that having olfactory dysfunction is 
associated with an increased risk of incident PD. For individuals with 
olfactory dysfunction in the total pooled population, the unadjusted 
odds ratio of PD diagnosis was 4.18 compared to individuals without 
olfactory dysfunction. Importantly, however, the risk seems to vary 
across subgroups. In particular, in cohorts comprising a high percentage 
of women or containing exclusively individuals with confirmed RBD, 
olfactory dysfunction seems to convey an elevated risk of incident PD. In 
addition, this risk was higher in cohorts with a shorter follow-up dura-
tion after the initial establishment of olfactory dysfunction. In the next 
paragraphs, we carefully interpret these findings in a broader context. 
There are three possible explanations for the observed higher risk 
estimate of olfactory dysfunction in studies with a higher percentage of 
women. First, olfactory dysfunction is more common in men than in 
women and its causes may be more heterogeneous, certainly in age 
groups at high risk of PD (>60 years) [25–27]. In particular, olfactory 
dysfunction may in some individuals reflect the prodromal phase of 
another neurodegenerative disease than PD, such as Alzheimer’s disease 
[28,29]. Intriguingly, olfactory dysfunction may have higher predictive 
value for mild cognitive impairment in men than in women, indicating 
that the predictive value of olfactory dysfunction in men and women 
may differ between neurodegenerative diseases [28]. Large, prospective 
studies with robust monitoring and clinical assessment of incident PD 
and Alzheimer’s disease are warranted to determine whether there are 
true sex differences in the association between olfactory dysfunction and 
incident neurodegenerative diseases. Second, the routes of spread of 
synucleinopathy may differ between men and women as a result of 
hormonal effects. However, previous research suggests that estrogen is 
likely to protect instead of harm olfactory bulb tissue [30–32]. Lastly, 
there is some debatable evidence that olfactory identification in women 
is superior to men’s in neurodegenerative as well as physiological con-
ditions, lowering the risk of olfactory identification for Parkinson’s 
disease specifically [33–35]. In a broader context, it is notable that in PD 
research, women are generally underrepresented [36], and our obser-
vation that the risk of PD associated with a prominent prodromal PD 
marker varies by the distribution of sex in a population highlights the 
need to consider sex-specific estimates in future prodromal PD criteria 
updates. Furthermore, we note that the sex-related meta-regression 
analyses were significantly influenced by the male-only Honolulu Study 
[24]. In studies that examined effect modification at an individual rather 
than a group level, effect estimates of olfactory dysfunction were actu-
ally higher among men, which further adds to our cautious interpreta-
tion of sex-specific differences in risk estimates [12,21]. 
The association between olfactory dysfunction and risk of PD after a 
shorter study follow-up period might indicate that olfactory dysfunction 
is indeed an imminent marker for PD. Interestingly, we observed that the 
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risk may decrease with time if individuals remain free of clinical PD 
beyond the first years of follow-up. In those individuals, it seems more 
likely that olfactory dysfunction is caused by a different pathology. The 
observation of a time-varying association is congruent with the olfactory 
vector hypothesis as well as the Braak staging system, which suggest an 
ascending fashion of spread of α-synuclein in the human nervous system 
for at least a proportion of the PD population [4]. Another explanation 
for this finding should also be noted: the included studies with shorter 
follow-up durations more commonly consisted of cohorts at higher risk 
of PD. Indeed, a recent long-term study in patients with idiopathic ol-
factory dysfunction found that PD diagnosis was established 10.9 years 
on average after olfactory dysfunction onset [37]. Still, this observation 
highlights the need to consider time-varying effects in the prediction of 
incident PD in individuals with newly established olfactory dysfunction. 
Future studies could study this by including olfactory dysfunction as a 
time-dependent covariate in a survival analysis with PD diagnosis as 
primary outcome. In studies which assessed effect modification by dis-
ease duration at individual-level, there was no clear difference in effect 
estimates of olfactory dysfunction for incident PD between short- and 
long-term intervals. However, we also note that those studies were not 
specifically powered to address effect modification by disease duration 
[12,21]. 
We observed a substantially increased risk estimate of olfactory 
dysfunction for incident PD in studies comprising exclusively in-
dividuals with RBD, although the difference by RBD composition was 
statistically non-significant, likely due to a limited sample size. RBD is 
regarded as a sign of presence of neurodegeneration and a clear pro-
dromal marker of PD, mostly in males because of high sex-specific 
prevalence of RBD. Therefore, its presence together with olfactory 
dysfunction should raise considerable suspicion for a prodromal state of 
PD [19]. Postuma et al. recently published a multi-center RBD cohort 
study in which olfactory dysfunction was the second best predictor for a 
combined outcome of dementia and parkinsonism after objective motor 
testing [38]. We hypothesize that in the case of RBD, an underlying 
synucleinopathy is the most likely cause of olfactory dysfunction, 
whereas in community-dwelling populations, a broader spectrum of 
causes may underlie this feature. 
We hypothesized that the covariate study-level age was negatively 
associated with PD incidence in studies, as it is conceivable that young- 
onset olfactory dysfunction is likely to be more often pathological than 
older-onset olfactory dysfunction [39]. Instead, we observed a positive 
association between age and olfactory dysfunction. This finding might 
be explained by the fact that young-onset PD is more often caused by 
pathogenic mutations and earlier studies reported better olfaction in 
patients with Parkin and LRRK2 mutations compared to patients with 
idiopathic PD [40–43]. As previous research suggests that nonmotor 
symptoms in monogenic forms of PD might be less common, a less 
diffuse α-synuclein deposition might result in more isolated motor 
function-related symptoms [44]. 
Of note, three studies which are cited in the MDS research criteria for 
prodromal PD could not be included in this meta-analysis, either 
because the study’s estimates compared the worst quartile of olfactory 
performance to only the best quartile of the population [5] or because 
the study comprised less than 5 converters to clinical PD [45,46]. A key 
limitation of this study is that summary statistics were pooled from 
studies that were heterogeneous in several key aspects. As a conse-
quence, our data provide insight on how the odds ratio of olfactory 
dysfunction for PD varies by the population mean of a key characteristic 
but do not yield characteristic-specific estimates. For instance, we show 
that the odds ratio is higher in studies with a higher percentage of 
women, but we could not calculate an odds ratio specific to women. In 
addition, studies were heterogeneous in definition of olfactory 
dysfunction and the choice of the olfactory function testing instrument. 
However, each of the instruments used assesses odor identification, and 
scores between UPSIT, B-SIT and SS-12 or SS-16 can reliably be trans-
formed. [47] Therefore, we considered it admissible to meta-analyze 
data based on different instruments in this study. We also added olfac-
tory testing instrument as a covariate in the meta-regression analyses 
and observed that it did not modify the observed results independently. 
We also note that analytical methods varied substantially across the 
included studies and some studies had a very low number of incident PD 
cases. To avoid inflation of risk estimates due to this, one study that 
pooled study results was included as the individual cohorts did not meet 
the inclusion criteria [10]. This does not take into account potential 
heterogeneity between these cohorts. Furthermore, summary statistics 
were used for (sub)group risk estimation, which meant that we had to 
make several statistical assumptions in pooling the data. Our pooled risk 
and subgroup estimates from high-risk cohorts, not based on individual 
patient data, should therefore be interpreted with caution. We consider 
these estimates to be an indication rather than robust quantification of 
true (biological) differences. An additional Knapp-Hartung sensitivity 
analysis, which further increases robustness in random effects 
meta-regressions with high heterogeneity compared to the 
DerSimonian-Laird estimator, increased p-values of age, sex and 
follow-up duration to non-significant values. Our observations should 
therefore encourage the initiation of collaborative efforts based on in-
dividual patient data to robustly quantify subgroup differences to allow 
for more personalized risk estimates [7]. Still, our observation of sub-
group differences provides important novel insight on the prodromal 
phase of PD and set our study apart from an earlier meta-analysis on the 
association of olfactory dysfunction and PD [48]. 
Table 2 
Olfactory dysfunction and incident Parkinson’s disease: unadjusted odds ratio across various subgroups of studies at baseline.    
Pooled OR* 95% CI p-value of difference Number of studies (references) 
Total population  4.18 2.47–7.07  8 [12,24,21,19,10,20,22,23]  
Follow-up <6.2 years 7.96 2.58–24.56  4 [19,20,22,23]  
≥6.2 years 2.73 2.09–3.57 0.07 4 [12,24,21,10]  
Age <66.8 2.91 2.00–4.22  4 [19,10,20,22]  
≥66.8 4.70 1.88–11.76 0.34 4 [12,24,21,23]  
Female % <47.1% 2.69 1.81–4.00  4 [24,19,10,22]  
≥47.1% 6.01 2.46–14.67 0.11 4 [12,21,20,23]   
Cohort population High-risk 9.39 2.42–36.49  3 [19,22,23]  
Community 2.75 2.11–3.58 0.08 5 [12,24,21,10,20]  
RBD 5.75 1.16–28.53 0.681 2 [19,22] 
Cut-offs of the subgroups are defined by the median follow-up, age and female percentage, respectively. CI = confidence interval, RBD = REM-sleep behavior disorder. 
1 versus non-RBD * Odds ratio is pooled per subgroup for mean study follow-up, mean study age and study female percentage, and for RBD cohorts, high-risk cohorts 
and community-dwelling cohorts. 
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Fig. 1. Hyposmia and incident Parkinson’s disease: unadjusted (A) and age- and sex-adjusted (B) odds ratios across studies Unadjusted odds ratios (left) and age- and 
sex-adjusted odds ratios (right). The articles by Fereshtehnejad, Jennings, Mahlknecht (2016) and Montgomery did not contain age- and sex-adjusted odds ratios. 
Pooled unadjusted OR of all studies that reported an adjusted OR (2.73 [CI 95% 2.09–3.57]) was lower than the pooled adjusted OR (B). 
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Fig. 2. Olfactory dysfunction and incident Parkinson’s disease: Visualization of study-level covariates sex and follow-up duration.  
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5. Conclusion 
This study suggests that olfactory dysfunction may signal imminent 
onset of clinical PD, especially in populations with a high proportion of 
women, higher age or individuals with RBD. Furthermore, the risk of 
clinical PD may subside over time if it does not occur in the first years of 
follow-up. Individual-patient data are needed to confirm these findings 
and to yield reliable, subgroup-specific risk estimates that could be used 
to refine criteria for prodromal PD and ultimately allow for earlier 
diagnosis and neuroprotective treatment. 
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